Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Dec 06, 2022 10:33am
147 Views
Post# 35153247

Dec. 16th

Dec. 16thTen days to go until this current Private Placement closes.  Adding $1,050,000 if the PP is fully subscribed.  The share price will not move from it's current level until the offering closes.  
It is now up to Andrew and the Directors to find some new investors and partners.  I would assume as we move closer to FDA submission for the Dermal Injector a few distribution partners will be announced. 
Once the Dermail Injector submission is announced sometime in Q1 those that have been skeptical about the devise will step up to the plate and buy in.
I still believe that Shiseido and Replicel will settle before the May 29th Hearing.  It could happen anytime. Now that I can see the light at the end of the tunnel I am more optomistic.

What I would like to see at this point is those that are selling the share price backwards would go away.
<< Previous
Bullboard Posts
Next >>